Retatrutide: A Chiropractor’s Guide to Navigating the Latest in Weight Loss Therapeutics

By Michael Dorausch, D.C.

A patient of mine came in this week saying they were taking “ret” and I immediately knew what they were referring to. My office is in Venice Beach and it’s already become a popular topic here. As chiropractors, staying informed about emerging medications like retatrutide is beneficial (to DC and patients), especially given its potential use in the fitness and wellness communities.

As a practitioner, you likely live a pharmaceutical free lifestyle (but that doesn’t mean your patients do). GLP-1s, peptides, TRT, creatine use, and now Retatrutide, are topics that come up during visits. It’s important to be informed.

Retatrutide (LY3437943) is an investigational medication developed by Eli Lilly as a triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously. Unlike dual agonists like tirzepatide (Mounjaro/Zepbound), this triple action enhances its effects on metabolism, making it a potential next-generation treatment for obesity, type 2 diabetes, and related conditions such as cardiovascular disease, knee osteoarthritis, and chronic low back pain.

It’s administered as a once-weekly subcutaneous injection and is still in clinical development, not yet approved by the FDA or any regulatory body for general use.

Currently, it’s only legally available through clinical trials, though some obtain it via unregulated gray-market sources like compounding pharmacies or online vendors.

What Does Retatrutide Do?

Retatrutide primarily promotes substantial weight loss by suppressing appetite, increasing energy expenditure, and improving insulin sensitivity.

It mimics natural gut hormones to regulate blood sugar, reduce food intake, and enhance fat burning, while also showing benefits for liver health, kidney function, and metabolic markers like cholesterol and blood pressure.

In addition to obesity, it’s being studied for conditions like type 2 diabetes, where it has demonstrated robust glucose-lowering effects.

Recent data also indicates potential relief from osteoarthritis pain and improved physical function in obese individuals.

Who’s Currently Using It?

Since retatrutide isn’t FDA-approved, its use is limited to participants in clinical trials or those accessing it through unregulated channels.

In the fitness and bodybuilding communities, it’s gaining popularity for “shredding” fat while preserving muscle, with users reporting dramatic body composition changes on doses as low as 4-12 mg weekly.

Gray-market users, including “gym bros” and online influencers, often share anecdotal experiences on platforms like X and TikTok, describing minimal hunger and rapid fat loss (e.g., 30 lbs in 2 months while maintaining muscle).

Safety and Effectiveness

Effectiveness: Clinical data shows retatrutide is highly effective, with phase 2 trials reporting average weight loss of 17-24% over 48 weeks – outperforming semaglutide (15%) and tirzepatide (20-22%). nejm.org +1 Phase 3 results from TRIUMPH-4 (December 2025) showed up to 28.7% loss (about 71 lbs) at 68 weeks in obese patients with knee osteoarthritis, plus significant pain reduction (75.8% on WOMAC scores).

It also improves HbA1c by 0.9-2%, fasting glucose, and blood pressure, with over 80% of high-dose users achieving 15%+ weight loss. Anecdotal reports from users echo this, with preserved muscle mass when combined with resistance training.

Safety: In trials, it’s generally well-tolerated, with a safety profile similar to other GLP-1 agonists – no significant increase in overall adverse events compared to placebo. Common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), mostly mild-to-moderate and dose-dependent, often mitigated by starting low. Other issues include temporary heart rate increases (peaking at 24 weeks) and rare hypoglycemia. Long-term safety is unknown, as trials are ongoing; potential risks include muscle loss if not exercising, or rare severe effects like psychosis in unregulated use. Gray-market versions may be contaminated or impure, leading to health risks, and the FDA has warned against unapproved sales. No deaths or severe hypoglycemia reported in studies.

Future Outlook (2027-2028)

Analysts project FDA submission in late 2026 or early 2027, with approval possible mid-to-late 2027 if trials succeed and no safety flags emerge. Commercial availability could follow in late 2027 or early 2028, depending on review type (standard 10 months or priority 6 months). It could become a blockbuster, potentially surpassing current GLP-1s in efficacy, but pricing, insurance coverage, and long-term data will influence adoption. Overall, it’s seen as another game-changer for obesity treatment, with broader applications in metabolic health.

Effective communication with patients about retatrutide starts with empathy and evidence-based dialogue, particularly as more individuals (including some in our practices) explore it for weight management. When patients mention using or considering it, chiropractors can discuss how it might interact with their spinal health or mobility goals. Encourage open conversations about side effects, like nausea or muscle preservation concerns, and advise consulting primary care physicians for monitoring. I like when my patients see other providers in their area of expertise, I prefer to focus on adjusting and chiropractic care.

The goal is knowledge and to be a source of that knowledge when patients seek it from us.